No profile data available.
Zymeworks Inc. (ZYME) is a healthcare company in the additional cancer treatment drugs industry, based in Middletown, United States, with about 231 full-time employees.
It reported revenue of $105.97 million for fiscal year 2025, up 38.9% from fiscal year 2024, and net income of -$81.13 million. Its market capitalization was $1.85 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
Zymeworks reported $105.97 million in revenue for fiscal year 2025, up 38.9% from $76.30 million in fiscal year 2024.
$1.85 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Zai Lab Limited (ZLAB), Hutchmed (China) Limited (HCM), Immunome, Inc. (IMNM), UroGen Pharma Ltd. (URGN).